Compared with placebo, dapagliflozin therapy improves the estimated glomerular filtration rate (eGFR) slope from 2 weeks to 12 months of treatment among heart transplant recipients, according to study results presented at the American Heart Association (AHA) Scientific Sessions 2026, held in Chicago, Illinois, from November 6 to 9, 2026.
In heart transplant recipients, progressive kidney disease is common due to preexisting comorbidities and calcineurin inhibitor exposure. However, there is limited evidence on the role of sodium-glucose cotransporter 2 (SGLT2) inhibitors on kidney function in this population.
The Dapagliflozin for Renal Protection in Heart Transplant Recipients (DAPARHT) trial is a double-blind, randomized, placebo-controlled trial that enrolled adult patients in Northern Europe from 6 heart transplant centers. Patients with type 1 diabetes and an active malignancy or receiving cancer treatment, as well as those receiving SGLT2 inhibitors, were excluded from the study.
In heart transplant recipients, dapagliflozin, compared with placebo, improved the slope of the eGFR from 2 weeks to 12 months of treatment.
Heart transplant recipients with at least 1 eGFR measurement after baseline and an eGFR of 25 mL/min/1.73 m2 or greater at least 1 year following transplantation were randomly assigned in a 1:1 ratio to receive 10 mg dapagliflozin or a matching placebo once daily.
The slope of eGFR from 2 weeks after treatment initiation to the end of a 12-month blinded treatment period was the primary study endpoint.
A total of 424 heart transplant recipients were included in the study, of whom 215 received dapagliflozin and 209 received placebo. Mean (SD) age of participants was 53 (14) years; 29% were women; eGFR at baseline was 67 mL/min/1.73 m2; and median (IQR) time from transplantation was 7 (3-13) years.
Compared with placebo, dapagliflozin improved the chronic slope of eGFR. For the dapagliflozin group, the change in eGFR from 2 weeks to 12 months after treatment initiation was 2.0 mL/min/1.73 m2 (95% CI, 1.0-3.1), compared with 0.3 mL/min/1.73 m2 (95% CI, -0.8 to -1.4) in the placebo group. The between group difference was 1.7 mL/min/1.73 m2 (95% CI, 0.1-3.3; P =.03).
There were similar adverse event rates between the 2 groups, with any adverse event occurring in 76.3% of patients in the dapagliflozin group and 71.1% of patients in the placebo group. No unexpected safety signals occurred in either group.
“In heart transplant recipients, dapagliflozin, compared with placebo, improved the slope of the eGFR from 2 weeks to 12 months of treatment,” the study authors concluded.
